ESR1 and breast cancer: Furthermore, although ERβ2 does not bind tested ER ligands, it is possible that compounds that inhibit its function can be identified, thus providing tools to further explore the function of ERβ2 as well as be used therapeutic agents, for example in breast cancers that express ERβ2.